Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules.

Inhibition of SARS-CoV-2 Entry into Host Cells Using Small Molecules.
复制标题

DOI:
10.3390/ph13120447
复制
发表时间:
2020-12-08
期刊:
Pharmaceuticals (Basel, Switzerland)
影响因子:
--
通讯作者:
Lee S
Lee S
中科院分区:
其他
文献类型:
--
作者:
Al Adem K;Shanti A;Stefanini C;Lee S

文献摘要

参考文献

被引文献

相似文献

严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 是一种属于冠状病毒家族的病毒,目前已知会引起冠状病毒病 (Covid-19),该疾病于 2019 年 12 月首次被发现。Covid-19 会导致从轻度感染到肺炎和肺衰竭等呼吸道疾病。引人注目的是,在首次报告后的几个月内,Covid-19 以异常高的速度在全球传播,并造成了巨大的人员伤亡。到目前为止,还没有针对 Covid-19 的具体治疗方法。设计能够干扰病毒进入过程的抑制药物是早期对抗 SARS-CoV-2 感染的主要预防疗法之一。在这篇综述中,我们简要介绍了冠状病毒的主要特征,讨论了SARS-CoV-2进入人类宿主细胞的机制,并综述了抑制SARS-CoV-2进入宿主细胞的小分子。具体来说,我们专注于通过实验验证和/或计算预测确定的小分子,这些小分子以 SARS-CoV-2 刺突蛋白、人血管紧张素转换酶 2 (ACE2) 受体和激活病毒融合的不同宿主细胞蛋白酶为目标。鉴于迄今为止 Covid-19 病例持续增加,应努力验证这些已确定的小分子抑制剂的治疗效果。
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), a virus belonging to the Coronavirus family, is now known to cause Coronavirus Disease (Covid-19) which was first recognized in December 2019. Covid-19 leads to respiratory illnesses ranging from mild infections to pneumonia and lung failure. Strikingly, within a few months of its first report, Covid-19 has spread worldwide at an exceptionally high speed and it has caused enormous human casualties. As yet, there is no specific treatment for Covid-19. Designing inhibitory drugs that can interfere with the viral entry process constitutes one of the main preventative therapies that could combat SARS-CoV-2 infection at an early stage. In this review, we provide a brief introduction of the main features of coronaviruses, discuss the entering mechanism of SARS-CoV-2 into human host cells and review small molecules that inhibit SARS-CoV-2 entry into host cells. Specifically, we focus on small molecules, identified by experimental validation and/or computational prediction, that target the SARS-CoV-2 spike protein, human angiotensin converting enzyme 2 (ACE2) receptor and the different host cell proteases that activate viral fusion. Given the persistent rise in Covid-19 cases to date, efforts should be directed towards validating the therapeutic effectiveness of these identified small molecule inhibitors.
冠状病毒的核衣壳蛋白在哺乳动物细胞中充当 RNA 沉默的病毒抑制剂。
DOI: 10.1128/jvi.01331-15
发表时间: 2015-09-01
影响因子: 5.4
作者:
Cui, Lei;Wang, Haiying;Chen, Yu
通讯作者: Chen, Yu
DOI: 10.1016/j.antiviral.2006.04.014
发表时间: 2007-05
期刊: Antiviral research
影响因子: 7.6
作者:
Ho TY;Wu SL;Chen JC;Li CC;Hsiang CY
通讯作者: Hsiang CY
DOI: 10.1056/nejmoa2016638
发表时间: 2020-08-06
影响因子: 158.5
作者:
Boulware, David R.;Pullen, Matthew F.;Hullsiek, Kathy H.
通讯作者: Hullsiek, Kathy H.
DOI: 10.1038/s41586-020-2575-3
发表时间: 2020-07-22
期刊: NATURE
影响因子: 64.8
作者:
Hoffmann, Markus;Moesbauer, Kirstin;Poehlmann, Stefan
通讯作者: Poehlmann, Stefan
DOI: 10.1128/jvi.01131-10
发表时间: 2010-11-01
影响因子: 5.4
作者:
Arndt, Ariel L.;Larson, Blake J.;Hogue, Brenda G.
通讯作者: Hogue, Brenda G.